Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs) Meeting Abstract
| Authors: | Bauer, S.; Lewis, J. H.; Gelderblom, H.; van de Sande, M.; Stacchiotti, S.; Healey, J. H.; Tap, W. D.; Wagner, A. J.; Pousa, A. L.; Druta, M.; Lin, C. C.; Baba, H. A.; Yver, A.; Shuster, D. E.; McGill, J.; Gu, X.; DeLeve, L. D. |
| Abstract Title: | Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz283.029 |
| Language: | English |
| ACCESSION: | WOS:000491295504356 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz283.029 |
| Notes: | Meeting Abstract: 1696P -- Appears on pages v695-v696 of the abstract book -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
